Abstract:Background: Previous studies demonstrated that adventitia fibroblasts exhibit important role in the hyperplasia of newly born endomembrane after blood vessel injury. However, the mechanism regarding phenotypic transition of adventitia fibroblasts in vitro remains unclear. Objective: To observe effect of peroxisome proliferators-activated receptor γ agonist (PPAR γ) on phenotypic transition of adventitia fibroblasts induced by transforming growth factor β 1 (TGF-β 1) in vitro, as well as the expression of collagen protein I. Design, Time and Setting: A randomized grouping control experiment was performed at the Tissue Engineering Laboratory of Ninth Affiliated Hospital of Shanghai Jiao Tong Medical College between July 2007 and October 2008. Materials: The aorta thoracica's adventitial fibroblasts were cultured from Sprague Dawley rats, with 2-month-old, weighing 120 g. The TGF-β 1 was supplied by American GenWay Biotech Company. The rosiglitazone power was purchased from Beijing Comens Chemical Co., Ltd. Methods: The experiment was divided into 3 groups: In the TGF-β 1 group, fibroblasts was induced with TGF-β 1 with different concentrations(3, 5, 10, 15 μ g/L) for 48 hours; in the rosiglitazone group, fibroblasts was induced with rosiglitazone (5, 10, 30, 50 μ mol/L) for 45 minutes followed by co-culture with 10 μ g/L TGF-β 1 for 48 hours. There was no intervention measure in the control group. Main Outcome Measures: The phenotypic transition of fibroblasts was measured by α-smooth muscle actin, the expression of smooth muscle α 2-actin, as well as collagen type I was determined by protein immunoblotting. Results: Compared with the control group, 5 μ g/L TGF-β 1 could significantly stimulate the changes of phenotypic transition of fibroblasts as well as the expression of smooth muscle α 2-actin and Collagen type I, which reach a peak level when treated with 10 μ g/L TGF-β, (P < 0.05). The expression of smooth muscle α 2-actin and collagen type I would not increase with the increasing of TGF-β 1 to 15 μ g/L, compared with 10 μ g/L TGF-β 1 group (P> 0.05). Compared with control group, 30 μ mol/L rosiglitazone could significantly inhibit changes of phenotypic transition of fibroblasts as well as the expression of smooth muscle α 2-actin and collagen type I (P<0.05). Conclusion: PPAR-γ agonist rosiglitazone can inhibit the phenotypic transition of adventitia fibroblasts induced by TGF-β 1, as well as the expression of smooth muscle α 2-actin and collagen type I.

PPAR-γ Agonist Can Inhibit Pulmonary Fibroblast to Myofibroblast Transition Induced by Fibronectin

Experimental study of inhibition of bleomycin-induced pulmonary fibrosis in rats by rosiglitazone

Rosiglitazone inhibits migration, proliferation, and phenotypic differentiation in cultured human lung fibroblasts.

PPAR-γ activation by rosiglitazone suppresses angiotensin II-mediated proliferation and phenotypictransition in cardiac fibroblasts via inhibition of activation of activator protein 1.

Peroxisome proliferator activated receptor gamma ligand suppresses hepatic fibrosis in rats

Effect of peroxisome proliferators-activated receptor gamma agonist on phenotypic transition of adventitia fibroblasts induced by transforming growth factor beta 1 in vitro

Rosiglitazone Inhibits Angiotensin II-induced CTGF Expression in Vascular Smooth Muscle Cells––role of PPAR-γ in Vascular Fibrosis

Rosiglitazone Abrogates Bleomycin-Induced Scleroderma and Blocks Profibrotic Responses Through Peroxisome Proliferator-Activated Receptor-Gamma.

Roles of peroxisome proliferator activated receptor-gamma in pulmonary fibrosis

Peroxisome Proliferator-Activated Receptor-γ(PPAR-γ) Agonists Attenuate the Profibrotic Response Induced by TGF-β1 in Renal Interstitial Fibroblasts

Inhibition of Rosiglitazone on the Proliferation, Connective Tissue Growth Factor and Smad Expression in Cultured Cardiac Fibroblasts Induced by Advanced Glycosylation End-Products

Protective Effects of Rosiglitazone on Non-Alcoholic Steatohepatitis in Rats

Effect of rosiglitazone on the secretion of chemokines in renal tubular epithelial cells stimulated by lipopolysaccharide and the possible mechanism

Agonists at PPAR‐γ Suppress Angiotensin II‐induced Production of Plasminogen Activator Inhibitor‐1 and Extracellular Matrix in Rat Cardiac Fibroblasts

Effects of peroxisome proliferator-activated receptor gamma on airway mucus production in a murine model of asthma

The impact of PPARγ on iNOS and its anti-ifbrotic effect in LX-2 cells

Effect of Fibronectin in Inducement of Pulmonary Fibroblast to Myofibroblast Transition

Effect of rosiglitazone on cardiac fibroblast proliferation, nitric oxide production and connective tissue growth factor expression induced by advanced glycation end-products.

Rosiglitazone Ameliorates Bile Duct Ligation-Induced Liver Fibrosis by Down-Regulating NF-κB-TNF-α Signaling Pathway in a PPARγ-dependent Manner.

Rosiglitazone inhibits receptor activator of NF-κB ligand expression in rheumatoid synovial fibroblasts through p-ERK pathway

Effects of rosiglitazone on myocardial fibrosis and expression of nuclear factorkappa B activation and connective tissue growth factor in diabetic rats